As reported by Nabet and colleagues (2020), fewer baseline circulating CD8+ T cells were associated with the clinical benefit of anti-PD1/PD-L1 therapy in patients with advanced NSCLC. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.